New results on alirocumab (Praluent) show that it is safe and effective for patients with familial hypercholesterolemia (FH), and yet these patients are faced with an unprecedented situation where some payers refuse to pay for the therapy, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
New results on alirocumab (Praluent) show that it is safe and effective for patients with familial hypercholesterolemia (FH), and yet these patients are faced with an unprecedented situation where some payers refuse to pay for the therapy, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Transcript
What do the results of ODYSSEY ESCAPE tell us about the safety of Praluent for patients with familial hypercholesterolemia?
These results of ODYSSEY ESCAPE really build on our continued knowledge of the safety and efficacy of Praluent for our patients who continue to live with FH. Now, ESCAPE specifically focused on those patients who required apheresis to help remove the cholesterol from their blood. And we’ve seen great results with Praluent being able to actually be both safe and effective for patients with FH, and, in fact, many patients actually probably don’t need as much apheresis when they’re taking Praluent.
Results presented at AHA show that of the patients who stopped taking Praluent, 30% did so because their payer would not pay or stopped paying for the therapy. Is there any precedent for this?
There’s no precedent for what we’re seeing in terms of the difficulty of our patients to be able to get Praluent when they’re prescribed. The appropriate patients for Praluent are those with FH or atherosclerotic cardiovascular disease who need additional [low-density lipoprotein] lowering on top of maximally tolerated statins. Those patients are having a really hard time about getting this when they’re prescribed. That’s really unprecedented.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More